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Abstract: Estrogen and hypoxia promote an aggressive phenotype in prostate cancer (PCa), driving
transcription of progression-associated genes. Here, we molecularly dissect the contribution of
long non-coding RNA H19 to PCa metastatic potential under combined stimuli, a topic largely
uncovered. The effects of estrogen and hypoxia on H19 and cell adhesion molecules’ expression were
investigated in PCa cells and PCa-derived organotypic slice cultures (OSCs) by qPCR and Western
blot. The molecular mechanism was addressed by chromatin immunoprecipitations, overexpression,
and silencing assays. PCa cells’ metastatic potential was analyzed by in vitro cell-cell adhesion,
motility test, and trans-well invasion assay. We found that combined treatment caused a significant
H19 down-regulation as compared with hypoxia. In turn, H19 acts as a transcriptional repressor of cell
adhesion molecules, as revealed by up-regulation of both β3 and β4 integrins and E-cadherin upon
H19 silencing or combined treatment. Importantly, H19 down-regulation and β integrins induction
were also observed in treated OSCs. Combined treatment increased both cell motility and invasion of
PCa cells. Lastly, reduction of β integrins and invasion was achieved through epigenetic modulation
of H19-dependent transcription. Our study revealed that estrogen and hypoxia transcriptionally
regulate, via H19, cell adhesion molecules redirecting metastatic dissemination from EMT to a β
integrin-mediated invasion.
Keywords: lncRNA; estrogen; hypoxia; prostate cancer; tumor metastasis; H19; epigenetic modulators;
biomolecular analysis; targeted therapy
1. Introduction
Prostate cancer (PCa) is one of the most common cancers in developed countries [1]. Widespread
prostate-specific antigen (PSA) screening has revealed that most patients present localized disease [2],
for which radical prostatectomy (RP) and radiation therapy (RT) are standard treatments. However,
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within 10 years, 20%–40% of post-RP [3] and 30%–50% of post-RT [4] patients will experience
biochemical recurrence. On average, this precedes the appearance by eight years after RP of clinical
metastases [5,6] that are the major cause of complications and death [7]. For these patients, a successful
therapy is still unavailable, creating the need for additional prognostic markers and for molecular
targeted therapeutical strategies.
The tumor microenvironment plays a crucial role in tumor initiation and progression. PCa is a
hormone-dependent neoplasia in which ageing is a recognized risk factor. The decline in the androgen
to estrogen ratio occurring with ageing is of key relevance for PCa development [8]. Estrogen/estrogen
receptors signaling indeed plays a fundamental role in PCa carcinogenesis and progression [9,10].
Several evidences substantiated the contribution of both estrogen receptors (ERα or ERβ) and of
non-genomic estrogen pathways in PCa, although there are conflicting results about the role of ERβ,
commonly considered to play an anti-oncogenic role. In contrast to that, hormone naïve prostate
cancer, unlike high grade prostate in situ neoplasia, generally retains high levels of ERβ expression,
even in lymph node and bone metastasis [10], in favor of a pro-tumoral role, depending on cancer
stage [11,12]. Of note, ERβ is extensively expressed in the secretory luminal cell types, in both benign
and neoplastic lesions, as well as in prostate cancer stem cells.
A common feature of most solid tumors is a low oxygen tension, hypoxia, which induces
proliferation, survival, apoptosis, metabolism, migration, and inflammation [13]. In particular, it is
well established that both acute and chronic hypoxia co-exists in PCa providing a link between the
hypoxic microenvironment and resistance to current therapy and poor outcome [14,15]. The critical
molecular mediators of hypoxia, the hypoxia-inducible factors HIF-1α and HIF-2α, are stabilized
upon low oxygen tension and transcriptionally regulate multiple steps of tumorigenesis [16]. Despite
sharing similar structures and upregulation in many cancers, HIF-1α and HIF-2α do not appear to be
fully redundant in function, raising the possibility that they may have non-equivalent effects in the
neoplastic pathogenesis [17,18].
PCa progression and metastatization include alterations in epithelial–stroma interactions,
induction of cell migration, and modulation of both extracellular matrix (ECM) and cell adhesion
molecules [19,20]. Among the numerous cell surface and ECM molecules potentially involved, both
integrins and cadherins are critical contributors to prostate cancer and represent potential therapeutic
targets [21–23]. Integrins are transmembrane proteins consisting of heterodimeric α and β subunits
that play an important role by bridging cells to ECM and by transmitting external signals to the
cell nucleus, with a crucial role in tumor promoting exerted by laminin-binding integrins α3β1 and
α6β4 [24], as well as by αvβ3 for bone metastasis [25]. Cadherins are cell surface proteins involved
in homophilic cell–cell interactions influencing biological responses in complex ways [26]. The
calcium-dependent E-cadherin (CDH1) is known to suppress tumorigenicity, and several mechanisms
to impair CDH1 function were reported in cancer including epithelial to mesenchymal transition
(EMT) [27]. Overall, dysregulation of integrins and cadherins triggers several signaling pathways
determining cancer progression.
Numerous studies have shown the importance of long non-coding RNAs (lncRNAs) as modulators
of key cellular physiological processes, such as scaffold for epigenetic modifying complex or as
molecular sponge for miRNA [28], as well as in several pathologies such as cancer, including prostate
cancer [29]. Emerging evidence indicates that the oncofetal H19 lncRNA plays a critical role during the
complex process of tumorigenesis, starting from the early stages involving translational deregulation
and genomic instability, through proliferation imbalance and stress management to metastasis [30].
The function of H19 is still controversial, exhibiting a promoting role in oncogenesis [31–33], but
also acting as a tumor suppressor [34,35]. Thus, H19 may be capable of opposite functions largely
dependent on cell type and microenvironment. Furthermore, H19 is one of the most sensitive lncRNAs
to hypoxia [36] and estrogens [37]. Although evidence exists about the tumor suppressor role of H19
in metastatic PCa [29,38], the pathophysiological role of H19 in this cancer is not clearly elucidated.
Zhu and colleagues have shown that the ectopic overexpression of H19 in metastatic prostate cell lines
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significantly increases the level of miR-675 and represses cell migration [38]. Nevertheless, little is
known about a direct role of H19 itself in initiation and progression of PCa.
We previously demonstrated that signaling through ER, endothelial nitric oxide synthase (eNOS),
and hypoxia inducible factors (HIFs), drives transcription of genes mediating acquisition of aggressive
phenotype in PCa [39–43]. Among the non-coding RNAs modulated by estrogens in aggressive
PCa [40,41], H19 genomic region was highly enriched in eNOS-peaks. Here, we focused our attention
on the role of H19 in the molecular mechanisms by which estrogen and hypoxia signaling might favor
the acquisition of an aggressive phenotype in prostate cancer. We showed that H19 is upregulated
by estrogen or hypoxia, whereas it is reduced upon combined treatment. In turn, H19-dependent
transcription of cells adhesion molecules and induction of E-cadherin and β3 and β4 integrins were
observed upon combined treatment. Overall, these data reveal that combined stimuli switch tumor
dissemination program from EMT to a β integrin-mediated invasion.
2. Results
2.1. Response of H19 Transcripts to Combined Estrogen and Hypoxia
Our previous data obtained by chromatin immunoprecipitation-sequencing (ChIP-Seq) showed
that in response to estrogen, the transcriptional complex ER beta (ERβ) and eNOS is enriched on
chromatin, as compared with the control, especially along non-coding regions [40,41]. Here, we focused
on the H19 transcript, one of the lncRNAs most sensitive to estrogen [37] or hypoxia [36]. We found
that H19 is significantly induced by hypoxia and by estrogens in hormone-driven tumor cells, such as
breast and prostate cancer cells (Figure S1).
ChIP-Seq data (Figure 1a) showed that the H19 genomic region was highly enriched in eNOS-peaks,
especially after 17β-estradiol (E2) treatment, and that these peaks were present in prostate epithelial
luminal cells derived from aggressive primary cancer (C27IM, exclusively expressing beta isoform of
the estrogen receptor [39,42,43]), but not in normal human primary umbilical vein endothelial cells
(HUVECs). The H19 gene locus is a complex region; it can be transcribed in both sense and antisense
directions (Figure 1b), producing from one strand H19 and the miR-675, embedded in H19’s first exon,
and from the opposite strand, the transcript coding the HOTS protein and the antisense 91H. We
focused on the response to estrogen and hypoxia of the non-coding transcripts, H19, miR-675, and 91H,
in aggressive PCa cells. H19 was induced by hypoxia (1% O2, Hyp) or estrogen (10−7 M, 17β-estradiol,
E2) at 6 h of treatment, a timing based on the previous time course for combined treatment [39].
Importantly, estrogen plus hypoxia (Hyp+E2) caused a significant downregulation of H19 expression
as compared with hypoxia alone (Figure 1c). The primiR-675 was also downregulated, whereas the
antisense transcript 91H was induced (Figure 1c).
To understand whether the H19 downregulation was specific for aggressive PCa, H19 expression
was evaluated in normal cell lines (HUVEC), in cells derived from non-aggressive PCa (C38IM), and in
metastatic PCa cell lines (PC3). As shown in Supplementary Figure S2, in HUVECs, the H19 level was
not altered by estrogen or hypoxia, alone or in combination, while in C38IM, it was induced by hypoxia
alone, but not altered by estrogen in combination. On the contrary, in the metastatic cell line PC3,
a significant H19 downregulation was observed upon combined treatment as compared with hypoxia
alone. These data suggest a specific downregulation of H19 expression upon combined treatment at
least in aggressive prostate cancer cells (C27IM and PC3).
To corroborate these findings, we investigated the response of the H19 gene products to chemical
hypoxia using cobalt chloride (100 µM, CoCl2). As shown in Supplementary Figure S3, H19 and
primiR-675 were downregulated in C27IM under combined chemical hypoxia plus estrogen treatment,
while the antisense transcript 91H was upregulated. Remarkably, this upregulation upon the double
stimuli is in agreement with the oncogenic function of 91H reported in several tumors [44]. Furthermore,
it is in agreement with the well-known regulation of classical hypoxia and estrogen target genes,
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such as the vascular endothelial growth factor receptor 2 (KDR, Figure S3d) and erythropoietin (EPO,
Figure S3e), which exert a driving role in disease progression [39].Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 4 of 24 
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immunoprecipitation (ChIP)‐Seq in normal human primary umbilical vein endothelial cells 
(HUVECs) and prostate cancer C27IM cells, before and after 17 β‐estradiol (10−7 M, E2). Red circle 
indicates the eNOS peak nearest to the H19 transcriptional start site. (b) H19 gene locus products, 
H19, miR‐675, HOTS and 91H, and direction of transcription showed by green (sense) and red 
(antisense) arrows. Specific primers for qPCR are indicated with black arrowheads. (c) H19, 
primiR‐675, and 91H RNA levels were assessed by quantitative RT‐PCR in C27IM after 6 h treatment 
with estrogens (E2, 10−7 M) and 1% O2 hypoxia (Hyp) alone or in combination (18 h for primiR‐675). 
Data, plotted as fold induction, represent mean ± SEM of three experiments. * p < 0.05 vs. NT; $ p < 
0.05 vs. E2; # p < 0.05 vs. Hyp. 
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Figure 1. Response of H19 locus transcripts to estrogen and/or hypoxia in single or combined treatment.
(a) Integrated Genome Viewer (IGV 2.1) screenshot showing H19 genomic region and endothelial nitric
oxide synthase (eNOS) peaks (blue boxes) identified by chromatin immunoprecipitation (ChIP)-Seq
in normal human primary umbilical vein endothelial cells (HUVECs) and prostate cancer C27IM
cells, before and after 17 β-estradiol (10−7 M, E2). Red circle indicates the eNOS peak nearest to
the H19 transcriptional start site. (b) H19 gene locus products, H19, miR-675, HOTS and 91H, and
irection of transcription showed by green ( ense) and red (antisense) arrows. Specific primers for
qPCR are indicated with black arrowh ads. (c) H19, p imiR-675, an 91H RNA levels were assessed by
quantitative RT-PCR in C27IM after 6 h treatment with estrogens (E2, 10−7 M) and 1% O2 hypoxia (Hyp)
alone or in combination (18 h for primiR-675). Data, plott d as fold induction, represent mean ± SEM
of three experiments. * p < 0.05 vs. NT; $ p < 0.05 vs. E2; # p < 0.05 vs. Hyp.
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2.2. Transcriptional Regulation of H19 upon Combined Treatment
To understand the molecular mechanisms underlying the H19 downregulation upon combined
stimuli, we investigated H19 transcription by parallel overexpression of HIF-1α or HIF-2α in the
presence or absence of estrogen (E2) in PCa cells (Figure 2a, Figure S4). In the absence of overexpression
(empty vector), E2 treatment significantly induced H19 expression (about 2-fold). Transfection of
exogenous HIF-1α or HIF-2α (white bars in Figure 2a, left panel) resulted in increasing H19 basal
expression, whereas estrogen treatment repressed the H19 level exclusively upon HIF-2α overexpression
as compared with control (empty vector plus estrogen treatment, black bars in Figure 2a, left panel).
Of note, levels of MALAT1, the well characterized lncRNA reported as a HIF-2α target [45], increased
upon HIF-2α, but not HIF-1α overexpression (Figure 2a, middle panel). Meanwhile, in the presence
of estrogen, it further increased, regardless of exogenous HIFs. Moreover, the hypoxia-target gene
GLUT1 was induced, as expected, by both HIF-1α or HIF-2α overexpression and by estrogen (Figure 2a,
right panel).
To confirm the selective involvement of HIF-2α, but not that of HIF-1α, in the H19 downregulation,
we evaluated changes in the H19 response to combined treatment in the VHL-deficient renal carcinomas
cells (786-O) that express endogenous HIF-2α, but not HIF-1α [46,47]. In this cellular context, H19 levels
decreased upon the combined treatment as compared with hypoxia or estrogen alone, whereas MALAT1
and GLUT1 were induced under the same experimental condition (Figure 2b).
To corroborate the above findings, modulation of H19 in 786-O cells upon single or combined
treatment was evaluated before and after HIF-2α silencing by small interfering RNA (Figure S5a).
Notably, HIF-2α silencing was capable of rescuing H19 transcript upon combined treatment in the
HIF-2α+ VHL-deficient renal carcinomas cellular context (Figure S5b). Similar results were obtained
also in C27IM cells (Figure S5c,d). Of note, a strong H19 increase in basal condition was observed upon
siHIF-2α in both cell lines, suggestive of a repressive role of HIF-2α in H19 regulation.
In addition, the H19 promoter was analyzed in C27IM by chromatin immunoprecipitation [42]
(ChIP) under individual or combined stimulus (estrogen and hypoxia). We previously observed that
several genes associated with progression were transcriptionally co-regulated by ERβ, HIFs, and eNOS
under combined treatment [39]. Chromatins were immunoprecipitated by antibodies to ERβ, HIF-2α,
or eNOS and DNA sequences proximal to or encompassing estrogen and hypoxia response elements
within H19 regulatory sequences were amplified. We focused first on the eNOS peak identified by
ChIP-Seq nearest to the transcriptional start site (TSS) and containing the previously reported hypoxia
responsive elements (red circle in Figure 1a and the work of [31]). Induction of eNOS, ERβ, and HIF-2α
recruitment was observed in response to estrogen or hypoxia. The combined treatment, as compared
with the single stimulus, caused a significant reduction in eNOS, ERβ, and HIF-2α recruitment at the
eNOS peak (Figure 2c, left). Similar results were obtained at the canonical estrogen responsive elements
located about −3500 bp from TSS (Figure 2c, right). These data suggest that both ERβ or HIF-2α interact
with chromatin at the estrogen and/or hypoxia responsive elements onto H19 promoter, whereas
eNOS acts as a partner of the combinatorial complex (according to previous results [39–41,43,48]).
Mechanistically, decreased recruitment of eNOS, ERβ, and HIF-2α and inhibition of H19 under the
combined treatment may be linked to the repressive complexes like histone deacetylases HDACs [41].
In line with this, the addition of a specific inhibitor of HDAC1/2 (Mocetinostat) [49] determined an
increase in the H19 level under combined treatment compared with the control (Figure S6).
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promoter regions, at the eNOS-peak outlined with a red circle in Figure 1a (left) and about 3500 bp
from the transcriptional start site (TSS) (right), of eNOS, ERβ, and HIF-2α by ChIPs after 2 h 15 min
treatment with estrogen (E2, 10−7 M) and 1% O2 hypoxia (Hyp), alone or in combination, in prostate
cells. No antibody (NoAb) served as the negative control. Values represent mean of three independent
experiments. * p < 0.05 vs. NT; $ p < 0.05 vs. E2; # p < 0.05 vs. Hyp.
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2.3. Cell Adhesion and Invasion Modulation Upon Combined Treatment
To investigate in vitro the metastatic potential of PCa cells, a cell–cell adhesion assay was first
performed [50]. The combined treatment induced cells aggregation in the presence of calcium (Ca2+),
compared with the control or single treatment (Figure 3a, Figure S7a), while reduced cell-adhesion in
the absence of Ca2+ (Figure 3b, Figure S7a). According to published data [51,52], E-cadherin (CDH1)
expression decreased upon estrogen or hypoxia, favoring EMT. In line with this, E-cadherin expression
decreased, while other EMT-related genes, Snail, Vimentin, and N-cadherin, increased upon single
stimuli (Figure 3c, Figure S7b,c). On the contrary, the combined treatment induced CDH1 expression at
both the mRNA and protein levels, and reduced the EMT-related genes (Figure 3c, Figure S7b,c), as well
as migration by scratch test (Figure S7d), thus suggesting that the EMT process is impaired in prostate
cancer cells under estrogen plus hypoxia stress. Given that an interdependent network between
cadherins and integrins has been proposed as crucial for the metastatic phenotype [53], we evaluated
the expression of several integrin subunits in our experimental setting. Of note, combined treatment
increased the β integrin subunits at the mRNA and protein levels, specifically β3 and β4 integrin
(ITGB3 and ITGB4, Figure 3d,e), known to preferentially mediate the interaction with vitronectin and
laminin 5 of the basal membrane, respectively. No modulation of the α2 integrin subunit gene (ITGA2)
or in the unrelated gene Runt-related transcription factor 2 (RUNX2) was instead observed (Figure 3d).
Moreover, the Laminin 5-enriched matrix cell-motility test revealed that combined treatment increased
cell adhesion and motility as compared with the control (Figure 3f). Of note, the overall aggressiveness
of PCa cells was highly induced by combined treatment, as revealed by an invasion test on Boyden
chamber (Figure 3g).
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Figure 3. Cell adhesion and invasion modulation upon single or combined treatment. (a,b) Cell–cell
adhesion assays were performed in the presence (Ca2+-dependent) or in absence (Ca2+-independent)
of 1mM Ca2+ using cells cultured for 18 h with E2 (10−7 M) or 1% O2 hypoxia (HYP) alone or in
combination (representative images in Figure S7a). Quantification of the in vitro cell–cell adhesion
assay in the presence (a) or in absence (b) of 1mM Ca2+ is plotted as percentage of occupied area
by cell aggregates. Data represent mean ± SEM of three independent experiments. (c) E-cadherin
mRNA level was assessed by quantitative RT-PCR in C27IM after 18 h treatment with E2 (10−7 M),
1% O2 (HYP), alone or in combination. Data, plotted as fold induction, represent mean ± SEM of three
experiments. (d) ITGB3, ITGB4, ITGA2, and RUNX2 mRNA level was assessed by quantitative RT-PCR
in C27IM after 18 h treatment with E2 (10−7 M) or 1% O2 hypoxia (Hyp) alone or in combination (48 h
for ITGB3). Data, plotted as fold induction, represent mean ± SEM of three experiments. (e) Protein
level analysis of β3 and β4 integrins in C27IM after 18 h treatment with E2 (10−7 M) or 1% O2 hypoxia
(HYP), alone or in combination (48 h for β3 integrin), performed by Western blot. Tubulin or β Actin
served as control. Molecular weight marker is indicated. Upper panels: representative experiments.
Lower panels: densitometric analysis, reported as fold induction vs. NT. (f) After a pre-treatment of
18 h under normoxia (NT) or estrogen (E2, 10−7 M) plus 1% O2 hypoxia (HYP+E2), cells were plated
on laminin-enriched matrix for 20 min. The results are expressed as percentage of adherent cells on
laminin-enriched matrix. Data represent mean ± SEM of three independent experiments. (g) Cell
invasion was examined by Boyden chamber after a pre-treatment of 48 h under normoxia (NT) or
estrogen (E2, 10−7 M) and hypoxia (100 µM CoCl2) alone or in combination. Left panel: representative
phase contrast microscopic images under 20×magnification (bright field) of invading cells. Right panel:
number of invading cells was presented, as fold induction vs. NT, as mean ± SEM of three independent
experiments. * p < 0.05 vs. NT, $ p < 0.05 vs. E2, # p < 0.05 vs. HYP or CoCl2.
2.4. H19 Mediates Transcriptional Repression of Cell Adhesion Molecules
In bladder cancer cells, it has been reported that (i) the formation of a complex between H19 and
the polycomb subunit EZH2 directly inhibits CDH1 expression by modulation of trimethylated lysine
27 of histone H3 (H3K27me3) level onto the CDH1 promoter [51], and (ii) a reduction of ITGB3 mRNA
occurs upon H19 overexpression [54]. We asked whether H19 is involved in cell-adhesion molecules’
regulation in the PCa context. H19 silencing by small interfering RNA (Figure 4a) determined an
increase of CDH1 as well as ITGB3 and ITGB4 mRNAs and protein level (Figure 4b–d). On the contrary,
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expression of ITGA2 and RUNX2 was unchanged (Figure 4c). Accordingly, H19 silencing increased the
level of both ITGB3 and ITGB4 in the basal condition and further increased CDH1, ITGB3, and ITGB4
levels upon single or combined treatment, whereas RUNX2 expression was unaffected (Figure 4e).
This suggests H19 acting as a transcriptional repressor of specific cell adhesion molecules.
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(CDH1) (b); ITGB3, ITGB4, ITGA2, and RUNX2 (c) mRNA levels quantified by qPCR in C27IM
transfected with siRNA specific to H19 (siRNA 19) or scramble. Data, plotted as fold induction siH19
vs. scramble, represent mean ± SEM of thre experiments. * p < 0.05 vs. scramble. (d) Protein analysis
of E-cadherin, β3, and β4 integrin before and after siRNA H19 by Western blot. Tubulin or β Actin
served as control. Molecular weight marker is indicated. Upper panels: representative experiments.
Lower panel: densitometric analysis, reported as fold induction vs. scramble, represent mean ± SEM
of three experiments. * p < 0.05 vs. scramble. (e) CDH1, ITGB3, ITGB4, and RUNX2 mRNA levels
quantified by qPCR in C27IM transfected with siRNA specific to H19 (siH19) or scramble for 48 h and
treated for additional 18 h with E2 (10−7 M), 1% O2 (HYP), alone or in combination. Data, plotted as
fold induction vs. scramble NT, represent mean ± SEM of three experiments. * p < 0.05 vs. scramble
NT, ˆ p < 0.05 vs. scramble.
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In line with this, the recruitment of EZH2 and level of H3K27me3 onto CDH1 as well as on ITGB3
and ITGB4 promoters decreased upon combined treatment (Figure 5a–c). Interaction on chromatin
between H19 and EZH2 in PCa cells was indeed confirmed by RNA-ChIP in the basal condition,
whereas the combined treatment specifically impaired this interaction (Figure 5d). Accordingly,
the recruitment of EZH2 and level of H3K27me3 onto CDH1 as well as on ITGB3 and ITGB4 promoters
decreased upon H19 silencing. No changes were observed in the control gene promoter RUNX2
(Figure 5e).
2.5. H19 and Integrin Modulation on Ex Vivo Organotypic Slice Cultures (OSCs) of Prostate Tumor upon
Combined Treatment
To evaluate whether the H19 downregulation observed in PCa cells was also detectable in tissue
samples from patients with prostate cancer (n = 10), a molecular analysis was performed using
organotypic slice cultures (OSCs) obtained from fresh surgical explants of organ-confined prostate
tumors, as in the work of [40] (Figure S8 and Table 1 for histopathological characteristics of PCa
patients). H19 expression was assessed in OSCs treated with 300 µM CoCl2. This concentration was
adopted because it was capable of inducing the hypoxia responsive gene GLUT1 (Figure S8b), alone
or in combination with estrogen. Seven OSCs were treated for 6 h with E2 and/or CoCl2 and H19
detected in five out of seven samples. Remarkably, a significant H19 downregulation was observed
upon combined treatment, as compared with single stimulus in all samples (Figure 6a). In order to
evaluate integrins expression under combined treatment, a subset of OSCs (n = 3) was treated with
estrogen and hypoxia for a longer time (48 h). As shown in Figure 6b, a significant increase of ITGB3
mRNA was detected in all samples upon individual and combined treatment, with the exception of
OSC-I being virtually responsive to the combined treatment alone. ITGB4 mRNA was responsive to
single treatment only in OSC-H, whereas combined estrogen and CoCl2 was effective in all three OSCs.
Note that the increase of β4 integrin was also observed at the protein level in OSC-L (Figure S8c).
These results, although very limited because of the small number of samples, show, at least as proof
of principle, that estrogen counteracts hypoxia in terms of H19 modulation also in the ex vivo PCa
samples, and are in agreement with previous data obtained in PCa cell lines.
2.6. Effects of Epigenetic Drugs on H19/Integrin Pathway upon Combined Treatment
We hypothesized that specific epigenetic drugs capable of affecting the H19/EZH2/H3K27me3
circuitry might contribute to normalizing the level of β integrin subunits under combined stimuli.
To this end, PCa cells were treated with estrogen plus hypoxia in the presence or absence of the
EZH2 or H3K27 demethylase JMJD3 specific inhibitors GSK-126 [55] and GSK-J4 [56], respectively.
As control, the level of the known EZH2-target gene, CDH1 and cyclin D1 [57], was increased and
decreased, respectively, with GSK-126 treatment (Figure S9). Treatment with GSK-J4, but not with
GSK-126, specifically normalizes the levels of both ITGB3 and ITGB4 (Figure 7a). Of note, an analysis
of H3K27me3 level on β3 and β4 integrins revealed that reduction observed upon combined stimuli
compared with control was further decreased in the presence of EZH2 inhibitor GSK-126. Conversely,
treatment with JMJD3 inhibitor GSK-J4 under estrogen plus hypoxia restored the basal level of
H3K27me3 on the promoters analyzed (Figure 7b). Notably, treatment with GSK-J4, but not GSK-126,
specifically inhibited PCa cells’ invasion by Boyden assays (Figure 7c).
These data suggest that blocking H19 action on integrins transcription may impair metastatic
potential upon combined treatment, providing evidence for a potential novel targeted therapy in
prostate cancer.
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upon combined treatment or H19 silencing. (a–c) Recruitment of EZH2 and H3K27me3 level on the
promoter region of CDH1 (a), ITGB3 (b), and ITGB4 (c) by ChIPs after 18 h treatment with estrogen
(E2, 10−7 M), 1% O2 hypoxia, alone or in combination in PCa cells (C27IM). No antibody (NoAb) served
as negative control. Values represent mean ± SEM of three independent experiments. * p < 0.05 vs. NT,
$ p < 0.05 vs. E2, # p < 0.05 vs. Hyp. (d) In vivo H19 interaction with polycomb subunit EZH2 before
and after Hyp+E2 (18 h) detected by RNA-ChIP assays. IgG was used as control. Immunoprecipitated
RNA was recovered and analyzed by qRT-PCR. The results are expressed as mean ± SEM of three
indep ndent experiments. * p < 0.05 EZH2 vs. IgG, $ p < 0.05 Hyp+E2 vs. NT. (e) Recruitment of
EZH2 and H3K27me3 level on the promoter regi n of CDH1, ITGB3, ITGB4, and RUNX2 by ChIPs
upon H19 silencing (siH19) compared with control (scamble, scr) i PCa cells (C27IM). Non-specific
immunoglobulin (IgG) served as negative control. Values represent mean ± SEM of three independent
experiments. * p < 0.05 vs. scramble.
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Table 1. Clinicalandpathologic featureofpatientsandtumors. PCa, prostatecancer; PSA,prostate-specificantigen.
PCa Patients Age PSA (ng/mL) PathologicGleason Score Pathologic Stage
A 61 8.5 7 (4 + 3) pT2c pNx pMx
B 63 5.36 7 (3 + 4) pT2c pNx pMx
C 70 18.04 7 (3 + 4) pT2c pN0 pMx
D 68 5.75 7 (4 + 3) pT3b pN0 pMx
E 55 6 7 (4 + 3) pT3b pN0 pMx
H 78 15 7 (4 + 3) pT3a pNx pMx
I 67 13.5 7 (4 + 3) pT2c pN0 pMx
L 66 8.5 7 (4 + 3) pT3b pN0 pMx
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Figure 6. H19 and integrin modulation on ex vivo PCa-derived organotypic slice cultures (OSCs) upon
single or combined treatment. (a) H19 levels were assessed by qPCR in OSCs from five different PCa
patients (OSC A–E) after 6 h treatment with E2 (10−7 M) and CoCl2 (300 µM), alone or in combination.
Data are plotted as fold induction vs. NT. (b) ITGB3 and ITGB4 levels were assessed by qPCR in OSCs
from three different PCa patients after 48 h treatment with E2 (10−7 M) and CoCl2 (300 µM), alone or in
combination. Data are plotted as fold induction vs. NT. * p < 0.05 vs. NT, $ p < 0.05 vs. E2, # p < 0.05
vs. CoCl2.
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estrogen (E2, 10−7 M) and hypoxia (100 μM CoCl2), in the presence or absence of EZH2 or JMJD3 
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Figure 7. Effects of epigenetic drugs on H19/integrin pathway. (a) ITGB3 (left) and ITGB4 (right) mRNA
levels were assessed by qPCR in C27IM after 18 h treatment with estrogen (E2; 10−7 M), 1% O2 hypoxia
(HYP), alone or in combination, in the presence or absence of inhibitor specific to EZH2 (GSK-126,
1 µM) or JMJD3 (GSK-J4, 1 µM) added 30 min before E2 and/or HYP. Data, plotted as fold induction
vs. Ctr/NT, represent mean ± SEM of three experiments. *p < 0.05 vs. NT, $ p < 0.05 vs. E2, # p < 0.05
vs. HYP, § p < 0.05 vs. HYP+ E2. (b) H3K27me3 level on the promoter region of ITGB3 and ITGB4
by ChIPs in C27IM cells treated as in panel a. Data represent mean ± SEM of three experiments. IgG
served as negative control. * p < 0.05 vs. NT, # p < 0.05 vs. Hyp. (c) Cell invasion was examined
by Boyden chamber after a pre-treatment of 48 h under normoxia (NT) or combination of estrogen
(E2, 10−7 M) and hypoxia (100 µM CoCl2), in the presence or absence of EZH2 or JMJD3 inhibitor added
as in (a). Vehicle (DMSO) was used as control. Left panel: representative phase contrast microscopic
images under 20× magnification (bright field) of invading cells. Right panel: number of invading
cells, presented as fold induction vs. NT DMSO, was mean ± SEM of three independent experiments.
* p < 0.05 vs. NT DMSO, # p < 0.05 vs. CoCl2 + E2 DMSO.
Int. J. Mol. Sci. 2019, 20, 4012 14 of 24
3. Discussion
Deciphering the mechanisms contributing to PCa metastatic progression is essential for discovering
therapeutic strategies. The main finding of our study resides on the downregulation of H19 under
combined estrogen and hypoxia stimuli, leading to induction of CDH1 and β3 and β4 integrin subunits,
a mechanism that profoundly changes and affects PCa metastatic potential.
Our previous studies in prostate cancer revealed that estrogen—and hypoxia—signaling act
synergistically to promote a specific gene transcription program towards the acquisition of an aggressive
phenotype [39]. Here, in agreement with the literature, we showed that H19 was induced by hypoxia
and by estrogen as single stimulus [36,37]. On the contrary, the combined treatment, hypoxia plus
estrogen, impaired H19 expression (Figure 1, Figures S2 and S3). These data were unpredictable
because H19, as with other cancer-associated lncRNAs, was expected to respond in a synergistic
manner upon the pro-tumor stimuli, hypoxia and estrogen, in line with previous results on classical
estrogen receptor and HIFs target genes, for example, KDR and EPO (Figure S3 and the work of [39]).
Mechanistically, H19 down-modulation upon combined stimuli appears to involve HIF-2α, but
not HIF-1α. HIF-2α silencing, in fact, was capable of rescuing H19 transcription in that experimental
condition (Figure S5). Moreover, recruitment of eNOS, ERβ, and HIF-2α was impaired upon
combined treatment along H19 regulatory regions, specifically at two relevant genomic loci (Figure 2c).
The relevance of a specific HIF-2α contribution is in line with previous results regarding the decrease of
survival in PCa patients with a higher level of nuclear eNOS and HIF-2α [39]. Here, we hypothesize that
one specific action of HIF-2α, at least in aggressive PCa, might be a direct inhibition of H19 transcription.
Regarding HIF-1α, our data suggest that H19 downregulation upon combined treatment does not
require HIF-1α function, as found in PCa and 786-O cells (Figure 2). These results are in line with the
previous observation about HIFα isoforms’ specific transcriptional selectivity [17,58]. Molecularly,
reduction of eNOS, ERβ, and HIF-2α recruitment and inhibition of H19 under combined treatment may
be the result of post-translation/conformation changes of proteins altering protein–protein interaction
with the transcriptional complexes. In this regard, based on our previous results on transcriptional
regulation of miR-34a in aggressive PCa [41], we found that inhibition mediated by estrogens requires
HDACs recruitment on target promoter. We also demonstrated the involvement of KMD1A and KMD4
demethylases in estrogen-mediated activation of hormone-target genes [40]. Moreover, emerging
evidence has indicated a small number of histone methyltransferases (HMTs) and histone demethylases
(HDMs) as regulators of ER signaling [59]. Here, we found that at least HDAC1/2 may affect the
level of H19 under combined treatment (Figure S6), advocating the contribution of specific repressive
complexes in H19 transcription regulation.
Some studies provided evidence suggesting that estrogen and hypoxic conditions per se can
trigger an EMT program, potentiating the invasive capacity of a variety of cancers [60,61], and
that estrogen-mediated signaling can either negatively or positively affect the hypoxia pathway,
depending on cell type [59,62]. Our finding about E-cadherin downregulation and upregulation of
EMT-related genes under hypoxia and estrogen alone is in agreement with induction of EMT in these
experimental conditions, whereas upon combined stimuli, we observed a specific upregulation of
E-cadherin, suggesting an EMT impairment (Figure 3c, Figure S7). Interestingly, E-cadherin increase
was paralleled by upregulation of theβ3 andβ4 integrin subunits upon combined treatment (Figure 3d,e,
Figure S7). The involvement of integrins in cell migration and spreading is well established [20],
suggesting that upon combined stimuli, changes in the cell-adhesion molecules’ pattern may promote
PCa aggressiveness via a mechanism residing in beta integrin-mediated motility, rather than EMT.
This conclusion is supported by our results on laminin 5-motility, invasion assays, and scratch tests
(Figure 3, Figure S7). Our data are also in line with previous findings demonstrating a role for
integrin β3 in PCa bone metastatization [25] and an overexpression of β4 integrin in advanced human
prostate cancer [63], and its association with aggressive behaviour and poor prognosis in several cancer
types [64].
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The co-expression of CDH1 and β integrins under combined stimuli is, moreover, in agreement
with the recently described cohesive metastatic phenotype in human prostate cancer [65]. Evidence on
PCa tissues revealed that aggressive PCa proceeds through a collective migration, a cluster of invasive
cells, rather than a single cell migration. Importantly, the cluster cells require both laminin-binding
integrins expression to ECM remodelling during migration, and cadherin expression to cell–cell
cohesion supporting collective migration (hybrid epithelial/mesenchymal phenotype). Our data
in PCa cells showed that combined estrogen and hypoxia treatment favours acquisition of both
epithelial cell–cell adhesion and mesenchymal motility traits. Here, we showed that change in
cell-adhesion molecule pattern is mediated by H19 function. Although previous data reported that H19
overexpression reduced ITGB3, ITGB5, and ITGA5 in bladder cancer cells [54] and increased ITGB1
and ITGA1 in pancreatic cancer cells [66], the molecular mechanism by which H19 regulates integrin
was not elucidated. Here, we provided evidence in favor of H19 acting as a repressor of transcription
of several cell-adhesion molecules, like CDH1, ITGB3, and ITGB4. Mechanistically, we demonstrated
that H19, by forming a complex with the EZH2, modulates H3K27me3 level and ultimately the rate of
transcription (Figure 5). In line with this, H19 silencing induced CDH1, ITGB3, and ITGB4 in the basal
condition, as well as upon single or combined treatment (Figure 4). At the same time, it reduced EZH2
recruitment and H3K27me3 level on target promoters (Figure 5). Moreover, although several reports
exist about estrogen or hypoxia as individual stimuli capable to induce beta integrin subunits [66–70],
this is the first time, to the best of our knowledge, that an increase in beta integrin subunits is reported
upon combined estrogen and hypoxia.
The results on PCa cells are also supported by data obtained in the ex vivo OSC model (Figure 6,
Figure S8), showing that, also in PCa fresh tissue explants derived from patients, the combined treatment
causes a specific H19 downregulation paralleled by β integrin subunits induction, a phenotype that
could be used as biomarker to define a specific subset of PCa patients. On the basis of these preliminary
data, we hypothesize that lower levels of basal H19 may be associated with the presence of both
hypoxic area and estrogens stimuli in prostatic tumors that, in turn, mediate an H19-dependent beta
integrin subunit induction. Further experiments will be required to investigate better this aspect.
Regarding the specific function of H19 in prostate cancer, an inhibitory role in cell migration for
the H19 internal microRNA, miR-675, has been identified in metastatic prostate cancer cell line by Zhu
and colleagues [38]. This activity as tumor suppressor is apparently in contrast with the upregulation
of H19 observed under estrogen or hypoxia alone (Figure 1, Figures S2 and S3). At the same time,
it appears to be in line with our results in terms of H19 downmodulation observed under combined
treatment and with the known key role played by hypoxia and estrogen in tumor aggressiveness.
Our data suggest that H19 may exert a different function in prostate cancer depending on tumor
properties and tumor microenvironment. Under hypoxia or estrogen alone, H19 level increases and,
through reduction of CDH1, induces EMT, exhibiting oncogenic properties. On the contrary, under
combined stimuli, H19 level is transcriptionally reduced, and CDH1 and β integrin expression released,
switching tumor dissemination toward an alternative mechanism, the cohesive phenotype, suggesting
a tumor suppressor role for H19 in this condition (Figure 8).
The correlation between H19 and integrins and their involvement in the acquisition of aggressive
phenotype potentially identify the H19/integrin pathway as novel target for designing molecular
therapy. In this regard, a specific effect of the JMJD3 inhibitor GSK-J4 in preventing ITGB3 and ITGB4
upregulation upon combined treatment was observed in PCa cells (Figure 7a). Notably, specific
JMJD3 inhibitor was able to significantly reduce invasion upon combined stimuli (Figure 7c). Future
experiments in pre-clinical models are necessary to evaluate the efficacy of JMJD3 inhibitors as
anti-tumor agents.
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USA; #PA5-19486), integrin β3 (Genetex, Irvine, CA, USA; GTX111672), Snail (Genetex GTX125918),
Vimentin (Bethyl, Montgomery, TX, USA; A301-620A-T), Laminin beta 1 (Abcam, Cambridge, UK;
ab108536), Fibrillarin (Thermo Fisher MA3-16771), HSP90 (StressMarq, Victoria, BC, Canada; SPC-104),
IgG (Normal Rabbit, Millipore, Burlington, MA, USA #12-370, Normal Rabbit, Bethyl #S120-101),
Tubulin (DM1A, Abcam #ab7291), β Actin (Abcam).
4.2. Cells and Treatments
Prostate epithelial luminal cancer (PCa) cell lines (C27IM and C38IM), PCa-metastasis-derived
PC3, HUVEC, MCF7, and MDA-MB-361 were cultured as in the work of [40]. Renal c rcinoma cells
786-O (VHL/HIF-1α deficient) were grown as in the work of [39]. The rat bladder epithelial cell ine
804G was grown as in the work of [71].
At least 72 h before experimental use, cells were switched to medium with hormone-deprived
serum and treated with 17β-estradiol (E2, 10−7 M; Sigma) for the times indicated in figur leg nds.
Mocetinostat2HBr (1 µM), EZH2 (GSK-126, 1µM) and JMJD3 (GSK-J4, 1 µM) inhibitors w re added to
cell cultures 30 min before estrogen and/or hypoxia treatments. Hypoxia condition was obt ined by
the chemical agent cobalt chloride (CoCl2, 100 µM) or by 1% O2, as in the w rk of [39].
4.3. RNA Extraction and Real Time PCR
RNA extraction, cDNA preparation, and real time PCR analysis were performed as in the work of [40]
on QuantStudio 5 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using SYBR Green
quantification. The relative amount of each gene was measured as fold change using the 2−∆∆Ct method
(β-Actin or P0 served as endogenous control). Expression ofβ-Actin, GLUT1, and primiR-675 were evaluated
by TaqMan method (Applied Biosystems). Primers for MALAT1 was as in the work of [40]. Primers sequences
were as follows: 91H 5′-GGCCCTGAATCAAACATCATG-3′ and 5′-TCACGCAGCGTTGCTCTCT-3′,
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CDH1 5′-CTGGGACTCCACCTACAGAAAGTT-3′ and 5′-CCAGAAACGGAGGCCTGAT-3′, EPO 5′-AG
CCCAGAAGGAAGCCATCT-3′ and 5′-GAAAGTGTCAGTGATTGTTC-3′, H19 5′-TCAAGCCTGGGCCT
TTGAAT-3′ and 5′-GGCTGATGAGGTCTGGTTCC-3′, ITGA2 and 5′-CAGCAATGTGGGAATCAGTATTACA-3′
and 5′-GGAAGGGCAGGGCTGAGT-3′, ITGB3 5′-GAAAACCCCTGCTATGATATGAAGAC-3′ and 5′-GTT
AGCGTCAGCACGTGTTTG-3′, ITGB4 5′-TGAAGAGCTGCACGGAGTGT-3′ and 5′-GGTCCCTGAACA
TCTCGTCTGT-3′, KDR 5′-CCAGCAAAAGCAGGGAGTCT-3′ and 5′-TGGTAGCCGCTTGTCTGGTT-3′,
P0 5′-TCGACAATGGCAGCATCTAC-3′ and 5′-ATCCGTCTCCACAGACAAGG-3′, RUNX2 5′-CCCGTG
GCCTTCAAGGT-3′ and 5′-TGACAGTAACCACAGTCCCATCTG-3′, HIF1α 5′-GAACAAAACACACAG
CGAAGCT-3′ and 5′-TGCAGTGCAATACCTTCCATGT-3′, HIF2α 5′- ATCAGCTTCCTGCGAACACA-3′
and 5′-CTTCGGCTTCGGACTCGTT-3′, CCND1 5′-CCGTCCATGCGGAAGATC-3′ and 5′-TGCAGGCGG
CTCTTTTTC-3′.
4.4. Transient Transfection Assays
Expression vectors were as described in the work of [39]. Plasmids were transfected into PCa cell
line using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Cells were grown in hormone-deprived serum for 72 h from transfection and treated with
17β-estradiol (E2, 10−7 M; Sigma) for 6 h before harvesting for RNA extraction.
4.5. Chromatin Immunoprecipitation (ChIP)
ChIPs were performed as in the work of [40]. Briefly, DNA fragments were recovered and analyzed by
qPCR using SYBR Master mix (Applied Biosystems, Foster City, CA, USA) with evaluation of dissociation curves
on QuantStudio 5 Real-Time PCR System (Applied Biosystems). Standard curves were generated by serially
diluting the input (5-log dilutions in triplicate). The specific sequences isolated by the immune-complexes were
analyzed by qPCR in duplicate and the data obtained were normalized to the corresponding DNA input control.
Data are represented as relative enrichment (fold induction over control ± treatment). Immunoprecipitations
were performed using specific antibodies to eNOS (BD Biosciences, BD610297, Franklin Lakes, NJ, USA), ERβ
(L-20, Santa Cruz Biotechnology #SC-6822, CWK-F12, DSHB, Dallas, TX, USA;), HIF-2α (Novus Biologicals
NB100-132, Centennial, CO, USA), EZH2 (D2C9, Cell Signaling, Danvers, MA, USA), and H3K27me3
(Active Motif #39156 and #39155, Carlsbad, CA, USA). No antibody or IgG (Bethyl. #P120-101, Montgomery,
TX, USA) were used as negative control. Primers sequences were as follows: H19prom (eNOS peak)
5′-GCCATGGCCCTTGATAGCTA-3′ and reverse 5′-TCCATATAGTCTCGACGTCATCCA-3′, H19prom
(-3500bp) 5′-CCTGTGTTCTGAGGTGATCATGA-3′ and 5′-GGCCTTGTGGGAAACGATT-3′; ITGB3prom
forward 5′-CGAGGCTCTTCATGGACCTATC-3′ and reverse 5′-ACCTACCTGTTGAGGGCAAGAC-3′,
ITGB4prom forward 5′-TGACCTGAACACCCGTGGTA-3′ and reverse 5′-GCACTCGATGCCTTGTTACAG
T-3′, CDH1prom forward 5′-CCGTGCAGGTCCCATAACC-3′ and reverse 5′-CATAGACGCGGTGACCCTC
TA-3′, RUNX2prom 5′- GCTCTGCTCTACAAATGCCTTAACCT-3′ and 5′-TCCGGCATCCAGAAGGATATAG-3′.
4.6. RNA Interference
Small interference to H19 and to HIF-2α was obtained with TriFECTa Kit DsiRNA Duplex
(Integrated DNA Technologies) transfected using Lipofectamine RNAiMAX (Invitrogen) according
to the manufacturer’s instructions and as in the work of [72]. Scrambled universal negative control
RNA duplex (NC1) was used. RNA was extracted after 48 h and chromatin was crosslinked after 18 h
from transfection.
4.7. RNA-Chromatin Immunoprecipitation (RNA-ChIP)
RNA-ChIPs were performed as in the work of [40] using specific antibodies to EZH2 (D2C9,
Cell Signaling #5246s) and IgG (Normal Rabbit, Millipore #12-370). The specific sequences isolated
by the immune-complexes were analyzed by real time PCR using the one-step method with SYBR
Green and specific primers (RNA-to-Ct 1 step kit; Applied Biosystems) and primer PCR assay H19
(#12004175 Bio-Rad, Hercules, CA, USA).
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4.8. Protein Extraction and Western Blot
Total protein extracts were obtained using RIPA buffer and nuclear/cytosolic extracts were prepared
as in the work of [39]. Western blot assay was performed using 40 µg of total extract and proteins were
resolved by SDS-PAGE using 7.5% or 4%−12% gradient Invitrogen Precast gel (NuPage and MES buffer).
The following primary antibodies were used: E-cadherin (1:2000, GeneTex GTX100443), β4 integrin
450-11A (1:1000), HIF-2α (1:500, Novus Biologicals, Centennial, CO, USA; NB100-132), HIF-1α(1:500,
Novus Biological NB100-105), N-cadherin (1:5000, Thermo-Fisher PA5-19486), integrin β3 (1:1000,
Genetex GTX111672), Snail (1:1000, Genetex GTX125918), Vimentin (1:1000, Bethyl A301-620A-T),
Fibrillarin (1:1000, Thermo Fisher MA3-16771), Laminin beta 1 (1:1000, Abcam ab108536), Tubulin
(1:5000, DM1A Abcam #ab7291), β Actin (1.1000, Abcam), and HSP90 (1:1000, StressMarq SPC-104C).
Specific protein signals were revealed with ECL Prime (Amersham, GE Healthcare, Boston, MA, USA)
and detected by UVIDOC (Eppendorf S.r.l., Hamburg, Germany). The intensity of each band was
evaluated using the NIH Image J 1.8 software (National Institutes of Health, Bethesda, MD, USA).
4.9. Cell–Cell Adhesion Assay
Cell–cell adhesion assay was performed as described in the work of [50] with minor modifications.
Briefly, after 18 h of 17β-estradiol (E2) and/or 1% O2 hypoxia treatment, a single-cell suspension was
prepared with 3 mmol/L EDTA in PBS−/−. Cells (6.6 × 105) were suspended in 1.6 mL complete medium
with 1 mmol/L CaCl2 (for Ca2+-dependent cell–cell adhesion) or 3 mmol/L EDTA (for Ca2+-independent
cell–cell adhesion) and plated on 60 mm bacterial Petri dishes and incubated at 37 ◦C on a shaking
platform for 60–90 min. Phase contrast images (bright field) were taken using a phase-contrast
microscope (AXIO microscope with AxioCam Erc5s, Zeiss- objective 10×) and the cell aggregated area
was measured with NIH Image J 1.8 software (National Institutes of Health, Bethesda, MD, USA).
4.10. Scratch Test
Scratch assay was performed as described previously in the work of [72]. Images were obtained
using a phase-contrast microscope (AXIO microscope with Axio Cam Erc5s, Zeiss- objective 10×,
Heidelberg, Germany) at time 0 and after 24 h, distance between edges was measured by the phase
contrast microscopy and analyzed by ZEN imaging software (Zeiss, Heidelberg, Germany). Data were
represented as percentage of the original gap.
4.11. Laminin 5 Cell Motility Test
A laminin 5-enriched matrix was prepared from 804G cells as previously described in the work
of [71]. Briefly, 2.5 × 105 cells were spread onto a laminin 5-enriched matrix for 20 min. Images were
obtained using a phase-contrast microscope (AXIO microscope with Axio Cam Erc5s, Zeiss-objective
10×, Heidelberg, Germany) at time 0 and after 20 min. Adherent cells on the laminin-enriched matrix
were counted using NIH Image J 1.8 software (National Institutes of Health, Bethesda, MD, USA). Data
were represented as percentage of adherent cells on laminin-enriched matrix.
4.12. Boyden’s Chamber Assay
Chemoinvasion assays were performed as in the work of [73] with minor modifications. Briefly,
2 × 104 cells, after 48 h pre-treatment with E2 and/CoCl2 100 µM, were placed in the upper compartment
of the Boyden’s chamber, in the presence or absence of E2 and/or CoCl2 and/or EZH2/JMJD3 inhibitors,
and after 16 h of incubation at 37 ◦C, invaded cells were fixed, stained with DiffQuick (Medion
Diagnostics, Dudingen, Switzerland), and counted. Each assay was performed in quadruplicate
and repeated at least three times. Images were obtained by Microscope OLYMPUS BX53 under
20×magnification.
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4.13. Organotypic Slice Cultures (OSCs) from Prostate Cancer Specimens
This study was authorized by the ethical committee of IRCCS-Fondazione Policlinico Gemelli-Università
Cattolica in Rome, Italy (IRCCS-Fondazione Policlinico Gemelli-UniversitàCattolica Protocol number: 232918/18;
ID:2133, date 21 June 2018) and informed consent was obtained from each patient. All procedures were
conducted according to the principles expressed in the Declaration of Helsinki, the institutional regulation, and
Italian laws and guidelines. PCa patients (n = 10) were enrolled at the Department of Urology, Università
Cattolica to perform prostatectomy with the following inclusion criteria: (i) clinically localized PCa at diagnosis
and (ii) absence of hormone treatment/radiotherapy before surgery. OSCs were generated as described in the
work of [40]. Medium was replaced daily and after three days, slices were treated with E2 (10−7 M) or CoCl2
(300 µM) alone or in combination, for the times indicated in figure legends, and then RNA and protein was
extracted using Trizol according protocol described in the work of [74].
4.14. Statistical Analysis
Data are expressed as mean ± SEM or as fold induction as indicated in figure legends. Significance
was calculated using a two-tailed t-test and/or one-way analysis of variance (ANOVA). Statistical
analysis was performed using Sigma Plot 13.0 statistical software. p values of <0.05 were considered
as significant.
5. Conclusions
Our data contribute elucidating the molecular basis underlying the acquisition of an aggressive
phenotype in PCa under combined estrogen and hypoxia stimuli, focusing on H19 modulation and its
impact on PCa biology. In particular, we demonstrated an important change in cell adhesion molecules,
which involves β3 and β4 integrin subunits triggered by H19 under combined treatment. We revealed
that H19 acts as a repressor of transcription of E-cadherin, as well as β3 and β4 integrins, by recruiting
EZH2 polycomb subunit and increasing H3K27me3 level at the promoter region. Under combined
treatment, we observed, at least in aggressive prostate cancer, a specific inhibition of H19 expression
that leads to the release of cell adhesion molecules transcription. This phenomenon is crucial for
the acquisition of aggressive and metastatic phenotype. Lastly, we demonstrated that epigenetic
modulation of H3K27me3 level may restore the basal level of β3 and β4 integrins, thus reducing
invasion capability. Finally, the effect of epigenetic drugs on the novel H19/integrin pathway might
represent an alternative/additional tool to modulate cell adhesion and invasion. This may impact the
metastatic potential and may be used to design innovative targeted therapies.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/16/
4012/s1.
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PCa prostate cancer
PSA prostate-specific antigen
RP radical prostatectomy
RT radiation therapy
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CDH1 E-cadherin
EMT epithelial to mesenchymal transition
lncRNAs long non-coding RNAs
ER estrogen receptor
eNOS endothelial nitric oxide synthase
HIFs hypoxia inducible factors
HOTS H19 Opposite Tumor Suppressor
E2 17β-estradiol
HYP hypoxia
CoCl2 cobalt chloride
qPCR quantitative polymerase chain reaction
KDR vascular endothelial growth factor receptor 2
EPO erythropoietin
ChIP chromatin immunoprecipitation
TSS transcriptional start site
HDAC histone deacetylases
VHL von Hippel-Lindau tumor suppressor
Ca2+ calcium
ITGB3 β3 integrin subunit
ITGB4 β4 integrin subunit
ITGA2 α2 integrin subunit
RUNX2 Runt-related transcription factor 2
H3K27me3 trimethylated lysine 27 of histone H3
OSCs organotypic slice cultures
CCND1 Cyclin D1
RNA-ChIP RNA chromatin immunoprecipitation
DMSO dimethyl sulfoxide
EDTA ethylenediaminetetraacetic acid
PBS phosphate-buffered saline
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